CCO Oncology Podcast artwork

The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

CCO Oncology Podcast

English - July 30, 2021 20:30 - 21 minutes - 20.1 MB
Courses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Managing Serious Adverse Events Associated with BTK Inhibitor Treatment
Next Episode: CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

In this episode, Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, discuss the clinical implications of the latest data on androgen receptor–targeting agents in the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). Topics include:

Updated safety and patient preference data from the ARAMIS and ODENZA trialsChoice of apalutamide, darolutamide, and enzalutamideCounseling patients on adverse eventsManaging patients with asymptomatic nonmetastatic CRPC

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Gustave Roussy
Villejuif, France  

Alicia K. Morgans, MD, MPH
Associate Professor
Division of Oncology
Department of Medicine
Northwestern University
Chicago, Illinois  

Link to full program, including downloadable slides:
https://bit.ly/36IEnNE